- HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
-
Soomin Ahn, Ji Won Woo, Kyoungyul Lee, So Yeon Park
-
J Pathol Transl Med. 2020;54(1):34-44. Published online November 6, 2019
-
DOI: https://doi.org/10.4132/jptm.2019.11.03
-
-
14,993
View
-
869
Download
-
57
Citations
-
 Abstract
 PDF
- Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification is found in about 20% of invasive breast cancers. It is a sole predictive marker for treatment benefits from HER2 targeted therapy and thus, HER2 testing is a routine practice for newly diagnosed breast cancer in pathology. Currently, HER2 immunohistochemistry (IHC) is used for a screening test, and in situ hybridization is used as a confirmation test for HER2 IHC equivocal cases. Since the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines on HER2 testing was first released in 2007, it has been updated to provide clear instructions for HER2 testing and accurate determination of HER2 status in breast cancer. During HER2 interpretation, some pitfalls such as intratumoral HER2 heterogeneity and increase in chromosome enumeration probe 17 signals may lead to inaccurate assessment of HER2 status. Moreover, HER2 status can be altered after neoadjuvant chemotherapy or during metastatic progression, due to biologic or methodologic issues. This review addresses recent updates of ASCO/CAP guidelines and factors complicating in the interpretation of HER2 status in breast cancers.
-
Citations
Citations to this article as recorded by  - Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
Lan Deng, Le Zhao, Lifen Liu, Haomin Huang
Open Life Sciences.2023;[Epub] CrossRef - Data on 2D culture characterisation of potential markers in human HER2-positive breast cancer cell lines
Son H. Pham, Lyn R. Griffiths, Rachel K. Okolicsanyi, Larisa M. Haupt
Data in Brief.2023; 46: 108880. CrossRef - Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
Christiane Palm, Catherine E. Connolly, Regina Masser, Barbara Padberg Sgier, Eva Karamitopoulou, Quentin Simon, Beata Bode, Marianne Tinguely
Diagnostics.2023; 13(1): 168. CrossRef - Gene amplification mutations originate prior to selective stress in Acinetobacter baylyi
Jennifer A Herrmann, Agata Koprowska, Tesa J Winters, Nancy Villanueva, Victoria D Nikityuk, Feini Pek, Elizabeth M Reis, Constancia Z Dominguez, Daniel Davis, Eric McPherson, Staci R Rocco, Cynthia Recendez, Shyla M Difuntorum, Kelly Faeth, Mario D Lopez
G3 Genes|Genomes|Genetics.2023;[Epub] CrossRef - Flow Rate-Independent Multiscale Liquid Biopsy for Precision Oncology
Jie Wang, Robert Dallmann, Renquan Lu, Jing Yan, Jérôme Charmet
ACS Sensors.2023; 8(3): 1200. CrossRef - Single-cell HER2 quantification via instant signal amplification in microdroplets
Xiaoxian Liu, Yifan Zhu, Caoxin Li, Yanyun Fang, Jinna Chen, Fei Xu, Yanqing Lu, Perry Ping Shum, Ying Liu, Guanghui Wang
Analytica Chimica Acta.2023; 1251: 340976. CrossRef - Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine
Daniela Miladinova
Frontiers in Molecular Biosciences.2023;[Epub] CrossRef - CORRELATION BETWEEN DIFFERENT CLINICOPATHOLOGICAL PARAMETERS AND MOLECULAR SUBTYPES OF FEMALE BREAST CARCINOMA IN SOUTH REGION OF IRAQ
Yassir Alaa Muhammed Hassan Shubbar
Wiadomości Lekarskie.2023; 76(1): 97. CrossRef - Design of a Ratiometric Plasmonic Biosensor for Herceptin Detection in HER2-Positive Breast Cancer
Neda Shahbazi, Rouholah Zare-Dorabei, Seyed Morteza Naghib
ACS Biomaterials Science & Engineering.2022; 8(2): 871. CrossRef - A highly sensitive nanobiosensor based on aptamer-conjugated graphene-decorated rhodium nanoparticles for detection of HER2-positive circulating tumor cells
Mahdi Sadeghi, Soheila Kashanian, Seyed Morteza Naghib, Esfandyar Askari, Fateme Haghiralsadat, Davood Tofighi
Nanotechnology Reviews.2022; 11(1): 793. CrossRef - Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Carrie S. Wynn, Shou-Ching Tang
Cancer and Metastasis Reviews.2022; 41(1): 193. CrossRef - Electroanalytical overview: screen-printed electrochemical sensing platforms for the detection of vital cardiac, cancer and inflammatory biomarkers
Robert D. Crapnell, Alejandro Garcia-Miranda Ferrari, Nina C. Dempsey, Craig E. Banks
Sensors & Diagnostics.2022; 1(3): 405. CrossRef - FTO genotype was associated with breast cancer in HER2 negative patients
Fateme Montazeri, Hossein Hatami, Soroor Fathi, Naeemeh Hasanpour Ardekanizadeh, Fatemeh Bourbour, Samira Rastgoo, Fatemeh Shafiee, Mohammad Esmail Akbari, Maryam Gholamalizadeh, Seyed Alireza Mosavi Jarrahi, Saeid Doaei
Clinical Nutrition ESPEN.2022; 49: 495. CrossRef - Breast Cancer Human Epidermal Growth Factor Receptor 2 mRNA Molecular Testing Compared to Immunohistochemistry with Correlation to Neoadjuvant Therapy Response
Mahmoud Behairy, Samia Mohamed Gabal, Mohamed Sherif Negm
Open Access Macedonian Journal of Medical Sciences.2022; 10(A): 352. CrossRef - Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review
Noortje Verschoor, Teoman Deger, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting, John W.M. Martens
Cancer Treatment Reviews.2022; 106: 102384. CrossRef - Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients
Hui Liu, Xiaoyan Hu, Lingyun Wang, Tao Du, Jing Feng, Ming Li, Lei Liu, Xiaofang Liu
Frontiers in Surgery.2022;[Epub] CrossRef - Use of Radionuclide-Based Imaging Methods in Breast Cancer
Betül Altunay, Agnieszka Morgenroth, Felix M. Mottaghy
Seminars in Nuclear Medicine.2022; 52(5): 561. CrossRef - Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer
Li Wang, Lei Yu, Jian Shi, Feng Li, Caiyu Zhang, Haotian Xu, Xiangzhe Yin, Lixia Wang, Shihua Lin, Anastasiia Litvinova, Yanyan Ping, Shangwei Ning, Hongying Zhao
Scientific Reports.2022;[Epub] CrossRef - Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
Anastasia Alataki, Mitch Dowsett
Endocrine-Related Cancer.2022; 29(8): R105. CrossRef - The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
Olga D. Bragina, Sergei M. Deyev, Vladimir I. Chernov, Vladimir M. Tolmachev
Acta Naturae.2022; 14(2): 4. CrossRef - Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations
Stephanie E. Siegmund, Danielle K. Manning, Phani K. Davineni, Fei Dong
Modern Pathology.2022; 35(10): 1458. CrossRef - Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
Matti Aapro, Fatima Cardoso, Giuseppe Curigliano, Alexandru Eniu, Joseph Gligorov, Nadia Harbeck, Andreas Mueller, Olivia Pagani, Shani Paluch-Shimon, Elzbieta Senkus, Beat Thürlimann, Khalil Zaman
The Breast.2022; 66: 145. CrossRef - Application of Fluorescence In Situ Hybridization Assisted by Fluorescence Microscope in Detection of Her2 Gene in Breast Cancer Patients
Fang Lu, Tingting Zhou, Yan Liu, Liying Song, Bin Zhang, Yuyan Li, Sorayouth Chumnanvej
Contrast Media & Molecular Imaging.2022; 2022: 1. CrossRef - High sensitivity label-free detection of HER2 using an Al–GaN/GaN high electron mobility transistor-based biosensor
Shivanshu Mishra, Pharyanshu Kachhawa, Amber Kumar Jain, Rajiv Ranjan Thakur, Nidhi Chaturvedi
Lab on a Chip.2022; 22(21): 4129. CrossRef - Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines
B. R. Nagarjun, Biren Parikh, Manaswi Nareshkumar Patel, Pina J. Trivedi, Dharmesh M. Patel
South Asian Journal of Cancer.2022; 11(04): 281. CrossRef - S‑phase fraction, lymph node status and disease staging as the main prognostic factors to differentiate between young and older patients with invasive breast carcinoma
António Pinto, João Matos, Teresa Pereira, Giovani Silva, Saudade André
Oncology Letters.2022;[Epub] CrossRef - Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling
Alina Batzilla, Junyan Lu, Jarno Kivioja, Kerstin Putzker, Joe Lewis, Thorsten Zenz, Wolfgang Huber, James Gallo
PLOS Computational Biology.2022; 18(8): e1010438. CrossRef - Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins
O. D. Bragina, V. I. Chernov, S. M. Deyev, V. M. Tolmachev
Bulletin of Siberian Medicine.2022; 21(3): 132. CrossRef - Molecular Pathology of Gastric Cancer
Moonsik Kim, An Na Seo
Journal of Gastric Cancer.2022; 22(4): 264. CrossRef - Loss of NECTIN1 triggers melanoma dissemination upon local IGF1 depletion
Julien Ablain, Amira Al Mahi, Harriet Rothschild, Meera Prasad, Sophie Aires, Song Yang, Maxim E. Dokukin, Shuyun Xu, Michelle Dang, Igor Sokolov, Christine G. Lian, Leonard I. Zon
Nature Genetics.2022; 54(12): 1839. CrossRef - Advanced diagnosis technologies for HER2 breast cancer markers
Mengxue Zhang
Highlights in Science, Engineering and Technology.2022; 14: 44. CrossRef - An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)
Aleix Prat, Aditya Bardia, Giuseppe Curigliano, M. Elizabeth H. Hammond, Sibylle Loibl, Sara M. Tolaney, Giuseppe Viale
JAMA Oncology.2022; 8(11): 1676. CrossRef - Development of T-cell engagers selective for cells co-expressing two antigens
Danielle M. Dicara, Sunil Bhakta, Mary Ann Go, James Ziai, Ron Firestein, Bill Forrest, Chen Gu, Steven R. Leong, Genee Lee, Shang-Fan Yu, Andrew G. Polson, Nicholas J. Agard
mAbs.2022;[Epub] CrossRef - The clinical significance of HER2 expression in DCIS
Ioanna Akrida, Francesk Mulita
Medical Oncology.2022;[Epub] CrossRef - Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2
Rachel Occhiogrosso Abelman, Arielle Medford, Laura Spring, Aditya Bardia
The Cancer Journal.2022; 28(6): 423. CrossRef - The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients
Ugur Gezer, Abel J. Bronkhorst, Stefan Holdenrieder
Diagnostics.2022; 12(12): 3042. CrossRef - Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li
Systematic Reviews.2022;[Epub] CrossRef - Interactions dietary components with expression level of breast cancer-related genes
Fatemeh Bourbour, Azam Pourtaheri, Khadijeh Abbasi, Naeemeh Hasanpour Ardekanizadeh, Maryam Gholamalizadeh, Azadeh Hajipour, Sepideh Abdollahi, Seyedeh Elaheh Bagheri, Mina Ahmadzadeh, Saeid Doaei, Arezoo Haghighian
Egyptian Journal of Medical Human Genetics.2022;[Epub] CrossRef - HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging
Betül Altunay, Agnieszka Morgenroth, Mohsen Beheshti, Andreas Vogg, Nicholas C. L. Wong, Hong Hoi Ting, Hans-Jürgen Biersack, Elmar Stickeler, Felix M. Mottaghy
European Journal of Nuclear Medicine and Molecular Imaging.2021; 48(5): 1371. CrossRef - Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
Christian Jackisch, Patricia Cortazar, Charles E. Geyer, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart
Cancer Treatment Reviews.2021; 99: 102229. CrossRef - Histologic Patterns of Cutaneous Metastases of Breast Carcinoma: A Clinicopathologic Study of 232 Cases
Shira Ronen, David Suster, Wei-Shen Chen, Natali Ronen, Sri Krishna C. Arudra, Celestine Trinidad, Doina Ivan, Victor G. Prieto, Saul Suster
The American Journal of Dermatopathology.2021; 43(6): 401. CrossRef - Standardized pathology report for breast cancer
Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon
Journal of Pathology and Translational Medicine.2021; 55(1): 1. CrossRef - The impact of oral contraceptive use on breast cancer risk: State of the art and future perspectives in the era of 4P medicine
R. Bonfiglio, M.L. Di Pietro
Seminars in Cancer Biology.2021; 72: 11. CrossRef - The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study
Yu-Xin Wang, Feng-Lian Li, Li-Xin Du, Jun-Fang Liu, Li-Gang Huo, Shu-Qing Li, Bin Tian
Cancer Management and Research.2021; Volume 13: 6123. CrossRef - Targeting HER2 protein in individual cells using ICP-MS detection and its potential as prognostic and predictive breast cancer biomarker
A. Fernández Asensio, M. Corte-Rodríguez, J. Bettmer, L.M. Sierra, M. Montes-Bayón, E. Blanco- González
Talanta.2021; 235: 122773. CrossRef - Development of a 99mTc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer
Lingzhou Zhao, Changcun Liu, Yan Xing, Jin He, Jim O’Doherty, Wenhua Huang, Jinhua Zhao
Molecular Pharmaceutics.2021; 18(9): 3616. CrossRef - WITHDRAWN: Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan
Bulletin du Cancer.2021;[Epub] CrossRef - Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
Emad A. Rakha, Islam M. Miligy, Cecily M. Quinn, Elena Provenzano, Abeer M. Shaaban, Caterina Marchiò, Michael S. Toss, Grace Gallagy, Ciara Murray, Janice Walshe, Ayaka Katayama, Karim Eldib, Nahla Badr, Bruce Tanchel, Rebecca Millican-Slater, Colin Purd
British Journal of Cancer.2021; 124(11): 1836. CrossRef - Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes
Catherine L. Wetzel, Thomas L. Sutton, Stuart Gardiner, Maryam Farinola, Nathalie Johnson, Jennifer R. Garreau
Journal of Surgical Oncology.2021; 124(8): 1224. CrossRef - Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy
Lun Li, Min Chen, Shuyue Zheng, Hanlu Li, Weiru Chi, Bingqiu Xiu, Qi Zhang, Jianjing Hou, Jia Wang, Jiong Wu
Frontiers in Oncology.2021;[Epub] CrossRef -
tRNA
‐derived fragments:
tRF‐Gly‐CCC
‐046,
tRF‐Tyr‐GTA
‐010 and
tRF‐Pro‐TGG
‐001 as novel diagnostic biomarkers for breast cancer
Yue Zhang, Zhao Bi, Xiaohan Dong, Miao Yu, Kangyu Wang, Xingguo Song, Li Xie, Xianrang Song
Thoracic Cancer.2021; 12(17): 2314. CrossRef - Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3
L. De Cock, J. Heylen, A. Wildiers, K. Punie, A. Smeets, C. Weltens, P. Neven, J. Billen, A. Laenen, H. Wildiers
ESMO Open.2021; 6(4): 100203. CrossRef - Standardized Pathology Report for Breast Cancer
Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon
Journal of Breast Cancer.2021; 24(1): 1. CrossRef - Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198
Jin-xiu Zhong, Yun-yuan Kong, Rong-guang Luo, Guo-jin Xia, Wen-xing He, Xue-zhong Chen, Wei-wei Tan, Qing-jie Chen, Yu-yin Huang, Yan-xing Guan
Journal of Translational Medicine.2021;[Epub] CrossRef - Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan
Bulletin du Cancer.2021; 108(11): 11S8. CrossRef - UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer
Evgenii L. Guryev, Anita S. Smyshlyaeva, Natalia Y. Shilyagina, Evgeniya A. Sokolova, Samah Shanwar, Alexey B. Kostyuk, Alexander V. Lyubeshkin, Alexey A. Schulga, Elena V. Konovalova, Quan Lin, Indrajit Roy, Irina V. Balalaeva, Sergey M. Deyev, Andrei V.
Molecules.2020; 25(18): 4302. CrossRef - Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
Min Chong Kim, Su Hwan Kang, Jung Eun Choi, Young Kyung Bae
Journal of Breast Cancer.2020; 23(5): 484. CrossRef
- Aquaporin 1 Is an Independent Marker of Poor Prognosis in Lung Adenocarcinoma
-
Sumi Yun, Ping-Li Sun, Yan Jin, Hyojin Kim, Eunhyang Park, Soo Young Park, Kyuho Lee, Kyoungyul Lee, Jin-Haeng Chung
-
J Pathol Transl Med. 2016;50(4):251-257. Published online June 7, 2016
-
DOI: https://doi.org/10.4132/jptm.2016.03.30
-
-
8,659
View
-
113
Download
-
17
Citations
-
Abstract
PDF
- Background
Aquaporin 1 (AQP1) overexpression has been shown to be associated with uncontrolled cell replication, invasion, migration, and tumor metastasis. We aimed to evaluate AQP1 expression in lung adenocarcinomas and to examine its association with clinicopathological features and prognostic significance. We also investigated the association between AQP1 overexpression and epithelial-mesenchymal transition (EMT) markers.
Methods
We examined AQP1 expression in 505 cases of surgically resected lung adenocarcinomas acquired at the Seoul National University Bundang Hospital from 2003 to 2012. Expression of AQP1 and EMT-related markers, including Ecadherin and vimentin, were analyzed by immunohistochemistry and tissue microarray.
Results
AQP1 overexpression was associated with several aggressive pathological parameters, including venous invasion, lymphatic invasion, and tumor recurrence. AQP1 overexpression tended to be associated with higher histological grade, advanced pathological stage, and anaplastic lymphoma kinase (ALK) translocation; however, these differences were not statistically significant. In addition, AQP1 overexpression positively correlated with loss of E-cadherin expression and acquired expression of vimentin. Lung adenocarcinoma patients with AQP1 overexpression showed shorter progression- free survival (PFS, 46.1 months vs. 56.2 months) compared to patients without AQP1 overexpression. Multivariate analysis confirmed that AQP1 overexpression was significantly associated with shorter PFS (hazard ratio, 1.429; 95% confidence interval, 1.033 to 1.977; p=.031).
Conclusions
AQP1 overexpression was thereby concluded to be an independent factor of poor prognosis associated with shorter PFS in lung adenocarcinoma. These results suggested that AQP1 overexpression might be considered as a prognostic biomarker of lung adenocarcinoma.
-
Citations
Citations to this article as recorded by - Aquaporins in Cancer Biology
Chul So Moon, David Moon, Sung Koo Kang
Frontiers in Oncology.2022;[Epub] CrossRef - A Comprehensive Prognostic Analysis of Tumor-Related Blood Group Antigens in Pan-Cancers Suggests That SEMA7A as a Novel Biomarker in Kidney Renal Clear Cell Carcinoma
Yange Wang, Chenyang Li, Xinlei Qi, Yafei Yao, Lu Zhang, Guosen Zhang, Longxiang Xie, Qiang Wang, Wan Zhu, Xiangqian Guo
International Journal of Molecular Sciences.2022; 23(15): 8799. CrossRef - Differential modulation of lung aquaporins among other pathophysiological markers in acute (Cl2 gas) and chronic (carbon nanoparticles, cigarette smoke) respiratory toxicity mouse models
Sukanta S. Bhattacharya, Brijesh Yadav, Ekta Yadav, Ariel Hus, Niket Yadav, Perminder Kaur, Lauren Rosen, Roman Jandarov, Jagjit S. Yadav
Frontiers in Physiology.2022;[Epub] CrossRef - Aquaporin water channels as regulators of cell-cell adhesion proteins
Sarannya Edamana, Frédéric H. Login, Soichiro Yamada, Tae-Hwan Kwon, Lene N. Nejsum
American Journal of Physiology-Cell Physiology.2021; 320(5): C771. CrossRef - Targeting Aquaporins in Novel Therapies for Male and Female Breast and Reproductive Cancers
Sidra Khan, Carmela Ricciardelli, Andrea J. Yool
Cells.2021; 10(2): 215. CrossRef - Targeting ion channels for the treatment of lung cancer
Liqin Zhang, Shuya Bing, Mo Dong, Xiaoqiu Lu, Yuancheng Xiong
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2021; 1876(2): 188629. CrossRef - Comprehensive Analysis of Aquaporin Superfamily in Lung Adenocarcinoma
Guofu Lin, Luyang Chen, Lanlan Lin, Hai Lin, Zhifeng Guo, Yingxuan Xu, Chanchan Hu, Jinglan Fu, Qinhui Lin, Wenhan Chen, Yiming Zeng, Yuan Xu
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef - Aquaporin 1, 3, and 5 Patterns in Salivary Gland Mucoepidermoid Carcinoma: Expression in Surgical Specimens and an In Vitro Pilot Study
Mérin Barbara Stamboni, Ágatha Nagli de Mello Gomes, Milena Monteiro de Souza, Katia Klug Oliveira, Claudia Fabiana Joca Arruda, Fernanda de Paula, Barbara Beltrame Bettim, Márcia Martins Marques, Luiz Paulo Kowalski, Clóvis Antônio Lopes Pinto, Victor El
International Journal of Molecular Sciences.2020; 21(4): 1287. CrossRef - Combined Systematic Review and Transcriptomic Analyses of Mammalian Aquaporin Classes 1 to 10 as Biomarkers and Prognostic Indicators in Diverse Cancers
Pak Hin Chow, Joanne Bowen, Andrea J Yool
Cancers.2020; 12(7): 1911. CrossRef - Aquaporins in lung health and disease: Emerging roles, regulation, and clinical implications
Ekta Yadav, Niket Yadav, Ariel Hus, Jagjit S. Yadav
Respiratory Medicine.2020; 174: 106193. CrossRef - Dissecting gene-environment interactions: A penalized robust approach accounting for hierarchical structures
Cen Wu, Yu Jiang, Jie Ren, Yuehua Cui, Shuangge Ma
Statistics in Medicine.2018; 37(3): 437. CrossRef - Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report
Giuseppe Angelico, Rosario Caltabiano, Carla Loreto, Antonio Ieni, Giovanni Tuccari, Caterina Ledda, Venerando Rapisarda
International Journal of Molecular Sciences.2018; 19(3): 685. CrossRef - Mechanisms of Aquaporin-Facilitated Cancer Invasion and Metastasis
Michael L. De Ieso, Andrea J. Yool
Frontiers in Chemistry.2018;[Epub] CrossRef - Aquaporin 1 suppresses apoptosis and affects prognosis in esophageal squamous cell carcinoma
Yuzo Yamazato, Atsushi Shiozaki, Daisuke Ichikawa, Toshiyuki Kosuga, Katsutoshi Shoda, Tomohiro Arita, Hirotaka Konishi, Shuhei Komatsu, Takeshi Kubota, Hitoshi Fujiwara, Kazuma Okamoto, Mitsuo Kishimoto, Eiichi Konishi, Yoshinori Marunaka, Eigo Otsuji
Oncotarget.2018; 9(52): 29957. CrossRef - Aquaporin 1 expression is associated with response to adjuvant chemotherapy in stage�II and III colorectal cancer
Hideko Imaizumi, Keiichiro Ishibashi, Seiichi Takenoshita, Hideyuki Ishida
Oncology Letters.2018;[Epub] CrossRef - Aquaporin 3 facilitates tumor growth in pancreatic cancer by modulating mTOR signaling
Xunwei Huang, Li Huang, Minhua Shao
Biochemical and Biophysical Research Communications.2017; 486(4): 1097. CrossRef - Prognostic implication of aquaporin 1 overexpression in resected lung adenocarcinoma†
Guido Bellezza, Jacopo Vannucci, Fortunato Bianconi, Giulio Metro, Rachele Del Sordo, Marco Andolfi, Ivana Ferri, Paola Siccu, Vienna Ludovini, Francesco Puma, Angelo Sidoni, Lucio Cagini
Interactive CardioVascular and Thoracic Surgery.2017; 25(6): 856. CrossRef
|
